AbbVie Exercises Option to Develop argenx Cancer Immunotherapy ARGX-115

AbbVie has exercised its exclusive license option to develop and commercialize argenx’s preclinical cancer immunotherapy ARGX-115, argenx said, making the Belgian biotech eligible for up to $625 million in milestone payments, plus royalties.AbbVie’s decision comes two months after the company paid argenx $10 million following achievement of a second unspecified preclinical milestone in the companies’ two-year-old collaboration.AbbVie paid argenx $10 million for achieving the fi